Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, Northwest Biotherapeutics Capital Limited, Northwest Biotherapeutics B.V., Advent BioServices Ltd., and others.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	273M 238M 225M 204M 383M 26.2B 384M 2.69B 1.04B 13.32B 1.03B 1B 42.86B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	369M 322M 304M 276M 517M 35.42B 519M 3.64B 1.4B 18.01B 1.39B 1.36B 57.95B	EV / Sales 2026 *	-	EV / Sales 2027 *	10.2x
Free-Float	95.22%	Yield 2026 *	-	Yield 2027 *	-

08-15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-07	Northwest Biotherapeutics and Saudi Pharmaceutical Industries and Medical Appliance Company Enter Memorandum of Understanding for Collaboration	CI
07-09	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma	CI
05-16	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-21	Northwest Biotherapeutics Establishes Dedicated Leukapheresis Clinic	CI
04-16	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-15	Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
11-15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-14	Northwest Biotherapeutics, Inc. announced that it expects to receive $4.75 million in funding from Yorkville Advisors Global LP	CI
01/11/25	Northwest Biotherapeutics, Inc. Enters into A Commercial Loan Agreement and Note with Streeterville Capital, LLC	CI
27/10/25	Northwest Biotherapeutics, Inc. announced that it has received $5.505 million in funding	CI
24/10/25	Northwest Biotherapeutics, Inc. completed the acquisition of Advent Bioservices Ltd from Toucan Holdings LLC.	CI
27/08/25	Northwest Biotherapeutics, Inc. entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million.	CI

08-15	Northwest Biotherapeutics: Q2 Earnings Snapshot	AQ
08-07	Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company	PR
07-09	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses	PR
07-03	Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting	PR
05-16	Northwest Biotherapeutics: Q1 Earnings Snapshot	AQ

Manager	Title	Age	Since
Alton Boynton CEO	Chief Executive Officer	82	01/06/2007
Linda Powers CEO	Chief Executive Officer	71	08/06/2011
Marnix Bosch CTO	Chief Tech/Sci/R&D Officer	67	01/01/2000

Director	Title	Age	Since
Alton Boynton BRD	Director/Board Member	82	01/01/1998
Linda Powers CHM	Chairman	71	17/05/2007
Navid Malik BRD	Director/Board Member	57	01/04/2012

Northwest Biotherapeutics, Inc. Stock Other OTC

Stocks

NWBO

US66737P6007

Biotechnology & Medical Research

Valuation: Northwest Biotherapeutics, Inc.

Latest news: Northwest Biotherapeutics, Inc.

Press Releases: Northwest Biotherapeutics, Inc.

Quotes and Performance

Managers and Directors: Northwest Biotherapeutics, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NORTHWEST BIOTHERAPEUTICS, INC.	-6.38%	-8.82%	-	-	282M
WUXI APPTEC CO., LTD.	-0.31%	+5.79%	+48.93%	+97.53%	70.89B
ARGENX SE	+0.39%	+2.06%	+40.91%	+78.49%	62.32B
INSMED INCORPORATED	-3.21%	-7.27%	-17.73%	+351.98%	27.07B
BIONTECH SE	-2.64%	-0.69%	-0.26%	-11.90%	24.78B
GENMAB A/S	+0.71%	+8.03%	+27.22%	-13.18%	20.59B
PHARMAESSENTIA CORPORATION	-1.26%	-7.81%	+169.33%	+302.38%	15.52B
EXELIXIS, INC.	-0.22%	+3.99%	+44.28%	+173.35%	14.49B
SUMMIT THERAPEUTICS INC.	+0.73%	+1.71%	-7.18%	+886.19%	14.14B
MADRIGAL PHARMACEUTICALS, INC.	-0.54%	-0.56%	+20.59%	+224.93%	12.35B
Average	-1.27%	+1.10%	+36.23%	+232.20%	29.13B
Weighted average by Cap.	-0.60%	+1.00%	+36.30%	+165.09%

	2026 *	2027 *
Net sales	-	38.93M 33.95M 32.06M 29.11M 54.54M 3.74B 54.77M 384M 148M 1.9B 146M 143M 6.11B
Net income	-	-
Net Debt	96.08M 83.78M 79.11M 71.84M 135M 9.22B 135M 948M 366M 4.69B 361M 353M 15.08B	125M 109M 103M 93.41M 175M 11.99B 176M 1.23B 476M 6.1B 469M 459M 19.61B